Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends

Heike Wulff, Neil A. Castle

Research output: Contribution to journalArticlepeer-review

123 Scopus citations


The Ca2+-activated K+ channel KCa3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. KCa3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K Ca3.1 and critically examine the available preclinical and clinical data validating KCa3.1 as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)385-396
Number of pages12
JournalExpert Review of Clinical Pharmacology
Issue number3
StatePublished - May 2010


  • Asthma
  • Atherosclerosis
  • Fibrosis
  • ICA-17043
  • K3.1
  • Restenosis
  • Sickle-cell disease
  • TRAM-34

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Therapeutic potential of K<sub>Ca</sub>3.1 blockers: Recent advances and promising trends'. Together they form a unique fingerprint.

Cite this